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Desaturase and elongase are two key enzyme categories in the long-chain 18 
polyunsaturated fatty acid (LCPUFA) pathway that convert dietary α-linolenic acid 19 
(18:3n-3) to docosahexaenoic acid (22:6n-3). The Δ6 desaturase is considered as rate 20 
limiting in the conversion. In a previous study in barramundi we demonstrated that the 21 
desaturase had a low Δ6 activity but noted that the enzyme also possessed Δ8 ability that 22 
utilised 20-carbon fatty acids. This observation suggests that an alternative pathway may 23 
exist in the barramundi via elongases to form 20-carbon metabolites from 18:3n-3 to 24 
20:3n-3 and then Δ6/8 desaturase to 20:4n-3. Cloning of the barramundi elongation of 25 
very long-chain fatty acid gene (ELOVL) and heterologous expression of the 26 
corresponding elongase were performed to examine activity with regard to time course, 27 
substrate concentration and substrate preference. Results revealed that the barramundi 28 
elongase showed a broad range of substrate specificity including 18-carbon PUFA 29 
(including 18:3n-3 and 18:2n-6), 20- and 22-carbon LCPUFA, with greater activity 30 
towards omega-3 (n-3) than n-6 fatty acids. The findings from this study provide 31 
molecular evidence for an alternative n-3 fatty acid elongation pathway utilising 18:3n-3 32 
in barramundi.  33 
 34 
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Dietary 18-carbon polyunsaturated fatty acids (PUFA) such as α-linolenic acid (18:3n-3) 39 
and linoleic acid (18:2n-6) are the essential precursors for biosynthesis of long-chain (LC) 40 
PUFA. The conventional n-3 LCPUFA pathway involves a Δ6 desaturation of 18:3n-3 to 41 
18:4n-3, followed by elongation to 20:4n-3 and then Δ5 desaturation to eicosapentaenoic 42 
acid (20:5n-3) and two consecutive elongations followed by a second Δ6 desaturation and 43 
a β-oxidation leading to docosahexaenoic acid (22:6n-3) [1]. Seven fatty acid elongases 44 
have been identified from mouse [2,3], rat [4], and human genomes [5,6] and are termed 45 
elongation of very long-chain fatty acid gene (ELOVL) subtypes 1−7. Among the 46 
mammalian elongase family, ELOVL5 uses a broad range of substrates including 16-47 
carbon monounsaturated fatty acids, 18-carbon PUFA and 20-carbon LCPUFA [4,7]. 48 
ELOVL2 is reported to preferentially elongate 22-carbon LCPUFA such as 49 
docosapentaenoic acid (22:5n-3) [8]. Together, ELOVL5 and ELOVL2 are utilised in 50 
endogenous PUFA synthesis to convert dietary essential fatty acid precursors 18:2n-6 and 51 
18:3n-3 to 24-carbon LCPUFA and eventually to generate 22:6n-3 [9,10].  52 
 53 
Beneficial effects of n-3 LCPUFA particularly 22:6n-3 and 20:5n-3 in human nutrition 54 
have been widely reported [11,12] and fish is recognised as a major source of these n-3 55 
LCPUFA in human diets [13]. Although aquaculture is widespread, the n-3 content of 56 
farmed fish is maintained by providing them with a feed containing fishmeal and/or fish 57 
oil [14]. However, the supply of wild fish for preparing these ingredients is limited, and 58 
the sustainability of aquaculture will ultimately rely on the ability of producers to make 59 
greater use of plant n-3 fatty acids. It is known that freshwater fish species are capable of 60 
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converting dietary 18:3n-3 into 20:5n-3 and 22:6n-3 via the desaturation and elongation 61 
pathway described above. Marine species, however, have a limited ability to convert n-3 62 
PUFA to n-3 LCPUFA, and it has been suggested that this may be due to the deficiency 63 
or impairment of their desaturation/elongation enzyme system [15].  64 
 65 
Barramundi (Lates calcarifer) is diadromous and thus is of particular interest in relation 66 
to LCPUFA biosynthesis because of the known differences in dietary PUFA requirements 67 
and enzyme capabilities of converting PUFA to LCPUFA between marine and freshwater 68 
species. We have previously demonstrated that barramundi desaturase has dual Δ6/Δ8 69 
activities which could use 18-carbon and 20-carbon fatty acids [16]. Interestingly, the 70 
barramundi Δ6/Δ8 dual function enzyme showed a higher preference for Δ8 than Δ6 71 
activity when encountering the substrate 20:3n-3 and this raises the potential for synthesis 72 
of n-3 LCPUFA from 18:3n-3 via a pathway that bypasses the initial Δ6 desaturase step 73 
in this species [16].  74 
 75 
The aim of the present study was to determine to what extent barramundi elongase has 76 
the capacity to synthesize n-3 LCPUFA from 18- and 20-carbon substrates, and in 77 
particular, whether the barramundi has the capacity to use 18:3n-3 and 18:2n-6 to form 78 
their 20-carbon elongation products for further processing by the Δ8 desaturase. 79 
Understanding the molecular basis of LCPUFA biosynthesis and regulation in 80 
barramundi will allow us to optimise the activity of the pathway to enable effective 81 
utilization of vegetable oil-based diets in barramundi aquaculture while maintaining the 82 
LCPUFA status of the farmed fish.  83 
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 84 
MATERIALS AND METHODS 85 
Chemicals 86 
Organic solvents used in this study were all analytical grade from Ajax Finechem Pty Ltd 87 
(Auckland, New Zealand) or Chem-Supply (SA, Australia). Fatty acids 18:3n-3, 18:2n-6, 88 
18:4n-3, 18:3n-6, 20:5n-3 and 20:4n-6 (all > 98-99% purity) were purchased from 89 
Cayman Chemicals (MI, USA). Fatty acid 17:0 was from Nu-Chek Prep, Inc (MN, USA) 90 
and 24:5n-3 was purchased from Larodan Fine Chemicals (Malmö, Sweden). Other 91 
chemicals and reagents were purchased from Sigma-Aldrich (MO, USA) unless specified 92 
otherwise.   93 
 94 
Barramundi 95 
The protocol was approved by the Animal Ethics Committee, University of Adelaide 96 
(Ethics number S-28-08). Juvenile barramundi (Lates calcarifer) were obtained from a 97 
commercial supplier (W. B. A. Hatcheries, SA, Australia).  98 
 99 
3’/5’ rapid amplification of cDNA end (RACE) 100 
RNA was isolated from barramundi liver using a Qiagen RNeasy kit (Qiagen, VIC, 101 
Australia) following the protocol provided by the manufacturer with the tissue initially 102 
disrupted using a Tissue Lyser (Mixer MM 300, Haan, Germany). All primers used in 103 
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this study were summarized in supplementary data 1. Barramundi ELOVL gene was 104 
obtained by a one-step reverse transcription polymerase chain reaction (RT-PCR) with 105 
primers designed from the conserved regions of the same genes of other species. The 106 
RACE protocol was modified from methods of Frohman [17] to obtain a full-length of 107 
the barramundi elongase gene. The cDNA for 3’ RACE was reverse transcribed from 108 
RNA using a hybrid primer (QtTVN) and reverse transcriptase (Omniscript RT, Qiagen) 109 
to generate a 3’end partial ELOVL sequences. PCR amplification was performed using 110 
Qo-R and Elovl3’raceGSP1-F primers with HotStar HiFidelity Polymerase (Qiagen).  111 
 112 
The nested PCR was performed using Elovl3’raceGSP2-F and Qi-R primers. To generate 113 
5’end partial cDNA clones, reverse transcription was carried out using RNA with the 114 
Elovl5’raceRT-R primer to synthesize first strand products. A polyA tail was appended to 115 
the cDNA template using terminal deoxynucleotidyltransferase (TdT) (Invitrogen, VIC, 116 
Australia) and dATP (Promega, NSW, Australia). PCR amplification was performed 117 
using the QtT-F primer to form the second strand of cDNA and Qo-F primer with the 118 
Elovl5’raceGSP1-R used for reverse transcription. A nested PCR was carried out using 119 
Elovl5’raceGSP2-R and Qi-F primers. Both 3’ and 5’RACE products of the ELOVL 120 
were sequenced and aligned with the partial gene fragments to identify the overlapping 121 
regions.  122 
 123 
Cloning and sequence analysis  124 
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Elovl-F and Elovl-R primers were designed for determining the full nucleotide sequence 125 
of the barramundi ELOVL, and ElovlEcoRI-F and ElovlXhoI-R were used to amplify the 126 
PCR product containing the putative ELOVL open reading frame (ORF). The putative 127 
barramundi ELOVL ORF was purified, restriction digested and inserted into EcoRI and 128 
XhoI sites digested pYES2 vector (Invitrogen) to yield the constructed plasmid 129 
pYES2/BarraELOVL. The barramundi elongase coding region was cloned and then 130 
sequenced (GenBank ID: GU047382) by pYES2-F and pYES2-R primers. The HotStar 131 
HiFidelity Polymerase Kit (Qiagen) with proofreading function was used throughout the 132 
cloning processes to minimize potential PCR errors. Sequence results indicated that the 133 
putative barramundi elongase gene included an ORF of 885 bp nucleotides specifying a 134 
protein of 294 amino acids. Parallel alignment of barramundi putative elongase 135 
(GenBank ID: GU047382, this study) with another barramundi elongase sequence 136 
(GQ214180) reported previously [18] indicated that the two barramundi ELOVL were 137 
100% identical in peptide sequence.  138 
 139 
Yeast transformation  140 
The pYES2/BarraELOVL plasmid was then transformed into Saccharomyces cerevisiae 141 
(INVSc1 yeast strain, Invitrogen) using S. c. EasyComp
TM
 Transformation Kit 142 
(Invitrogen). Transformed yeast cells were selected on synthetic minimal defined medium 143 




 plate) and supplemented with 2% 144 
glucose as the only carbon source. The transformant from a single colony was verified by 145 
DNA sequencing.  146 
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 147 
Heterologous expression and incubation of fatty acids 148 
An INVSc1 transformant colony containing pYES2/BarraELOVL construct was 149 
inoculated into SC
-U
 medium containing 2% glucose. The cells were grown overnight at 150 
27°C in an orbital incubator with vigorous shaking at 130 rpm. Expression of barramundi 151 
elongase was induced by transferring log-phase yeast cells (OD600nm = 0.4) into SC
-U
 152 
medium containing 2% galactose and 0.25% tergitol. Cultures were supplemented with a 153 
single fatty acid substrate from: 18:3n-3, 18:2n-6, 18:4n-3, 18:3n-6, 20:5n-3 and 20:4n-6, 154 
with concentrations of 250 μM for time course experiments, 0−500 μM for dose-response 155 
studies and 500 μM for a parallel comparison of substrate specificity. Yeast cells 156 
transformed with pYES2/BarraELOVL plasmid without galactose induction were used as 157 
negative controls. After 6, 12, 24, 48 and 72 hr (time course study) or 24hr (dose-158 
response and substrate specificity studies) incubation, yeast cells and culture media from 159 
individual culture with three independent replicates were harvested and total lipids were 160 
extracted and analysed as described below.  161 
 162 
Lipid extraction, methylation and gas chromatographic (GC) analysis 163 
All yeast cells from 10 ml culture from each treatment were harvested. One ml of cell-164 
free medium from each incubation was collected. Fatty acid 17:0 was added into each 165 
extraction tube as an internal standard. Total lipids were extracted from the samples by 166 
vigorous vortexing in chloroform-isopropanol (2:1, v/v) following a modified protocol of 167 
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Bligh and Dyer [19]. The resulting chloroform phase was evaporated to dryness under 168 
nitrogen gas, 1% sulphuric acid in methanol was added and transmethylation was 169 
performed. The fatty acid methyl esters were extracted with n-heptane, separated and 170 
quantified by GC as described previously [16].  171 
 172 
Statistical analysis 173 
A one-way analysis of variance (ANOVA) followed by Tukey-HSD test was used if P 174 
value less than 0.05 and the data followed Gaussian distributions. Kruskal-Wallis test 175 
with Dunn's multiple comparison test were applied for non-parametric analyses if data 176 
did not pass the normality test. Unpaired t-test was used to identify a difference between 177 
two groups. A probability level of 0.05 (P < 0.05) was used in all tests. Analyses were 178 
carried out with GraphPad Instat version 3.10 (GraphPad Software, CA, USA). 179 
 180 
RESULTS 181 
Elongation activity of the barramundi putative ELOVL  182 
Time course 183 
18:4n-3 and 20:5n-3 were used to examine the barramundi elongase expression activity 184 
because the peptide sequence alignment of the barramundi ELOVL with ELOVL2 and 185 
ELOVL5 in human, zebra fish and Atlantic salmon indicates a higher degree of 186 
homology with ELOVL5 (data not shown), and both 18:4n-3 and its downstream product, 187 
20:5n-3, are considered the main substrates for LCPUFA conversion by ELOVL5. 188 
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Following the addition of 18:4n-3 to transformed yeast cells expressing the barramundi 189 
ELOVL gene, the first elongation product, 20:4n-3, peaked at 6 hr but decreased to a 190 
lower constant level at all other time points (Fig. 1 A). In contrast, there was a linear 191 
increase with time of the next elongation product, 22:4n-3, in the yeast cells over the 192 
entire 72 hr of the incubation (Fig. 1 A). The concentration of extracellular elongation 193 
products (i.e. those in the culture medium) was also examined and a similar time course 194 
patterns were seen for 20:4n-3 and 22:4n-3, indicating secretion or diffusion of these fatty 195 
acids from yeast lipids into the medium (Fig. 1 B). There was also a significant decrease 196 
of 18:4n-3 in the medium within 6 hr, indicating the substrate was taken up by cells (Fig. 197 
1 B). When the total mass in yeast cell + medium is calculated, it is clear that within 6 hr, 198 
less than 5% of the original 18:4 n-3 substrate was left in the culture and around 12% was 199 
converted to 20:4n-3 and 22:4n-3 (Fig. 1 C). The substrate disappearance was also 200 
observed in the cultures with 20-carbon fatty acids. Approximately 25% of the 20:5n-3 201 
substrate was left in the culture and 10% of was converted to 22:5n-3 within 6 hr. 202 
However, 24:5n-3 was not detectable until 12 hr (Fig. 2 E and F). Elongation of 20:5n-3 203 
to 22:5n-3 showed a similar time course to that observed with 18:4n-3, except that there 204 
was very limited conversion to the second elongation product, 24:5n-3 (Fig. 1 D-F). 205 
Effect of substrate concentration 206 
With increasing concentrations of 18:4n-3 during 24 hr incubation, the production of 207 
20:4n-3 and 22:4n-3 in yeast cells increased linearly up to 500 μM of 18:4n-3 (Fig. 2 A) 208 
and a significant amount of 22:4n-3 was observed in the medium (Fig. 2 B). When the 209 
total mass in yeast cell + medium was calculated, it is clear that both elongation 210 
reactions, namely conversion of 18:4n-3 to 20:4n-3 and 20:4n-3 to 22:4n-3, effectively 211 
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preceded in a dose–dependent manner, and more than 95% of 18:4n-3 at 500 μM was 212 
elongated to 22:4n-3 (Fig. 2 C). With the addition of 20:5n-3 up to 500 μM there was an 213 
increase in the concentration of the first elongation product, 22:5n-3, in both cells and 214 
incubation medium but only low amounts of the second elongation product, 24:5n-3, in 215 
either the yeast or the medium (Figs. 2 D and E) suggesting limited ability of the 216 
transformed yeast cells to produce 24:5n-3. When summing the fatty acids in both the 217 
yeast cells and the medium for calculating the conversion rates, more than 90% of 20:5n-218 
3 at 500 μM was elongated into 22:5n-3 (Fig. 2 F). The ability of the transformed yeast 219 
cells to elongate 18:3n-3 to 20:3n-3, the potential bypass pathway of the LCPUFA 220 
conversion, is shown in Fig. 2 G-I. After the addition of 18:3n-3 to the transformed yeast 221 
cells, the elongation products 20:3n-3 plus a small amount of 22:3n-3 were detected in 222 
the yeast cells (Fig. 2 G) and the culture medium (Fig. 2 H). When the amount of all 223 
substrates and products in the yeast cells and medium were calculated, at 500 μM of 224 
18:3n-3, the conversion efficiency of 18:3n-3 to 20:3n-3 was above 60% (Fig. 2 I). 225 
Substrate preferences 226 
We compared substrate preferences for a range of n-3 fatty acids and their n-6 227 
homologues in the elongation pathway of LCPUFA. All fatty acid substrates were 228 
supplemented at 500 μM into yeast cultures and the cells incubated for 24 hr. When 229 
summing the fatty acids in both the yeast cells and the medium into account for 230 
calculating the conversion rates, there was a preference for n-3 over n-6 18-carbon fatty 231 
acids i.e. 18:4n-3 (97%) was preferred over 18:3n-6 (79%), and 18:3n-3 (62%) over 232 
18:2n-6 (23%) (Table 1). The n-3/n-6 preference was also significant (P = 0.02) between 233 
20:5n-3 and 20:4n-6.  234 
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 235 
The effect of induction of the barramundi ELOVL on endogenous yeast fatty acids, 236 
which are mainly saturated and monounsaturated fatty acids, was also examined. 237 
Induction of the enzyme increased the amounts of 18:1n-7, 18:1n-9 and 20:1n-9 in the 238 
cells significantly but there was no effect on endogenous saturated fatty acids (data not 239 
shown).   240 
 241 
DISCUSSION  242 
Using yeast as a heterologous expression model to examine the substrate specificity of 243 
the recombinant barramundi elongase, we observed that the barramundi ELOVL showed 244 
efficient activity at elongating the homologous pairs 18:4n-3 and 18:3n-6 as well as 245 
18:3n-3 and 18:2n-6 to their 20-carbon metabolites, albeit with lower efficiencies. The 246 
same pattern of elongation efficiency has been reported in other species [4,5,20]. The 247 
recombinant barramundi ELOVL also showed high efficiency for utilising the 20-carbon 248 
substrates 20:5n-3 and 20:4n-6 to produce 22-carbon products. In contrast, the 249 
recombinant enzyme only showed weak activity towards 22-carbon LCPUFA, indicating 250 
a high degree of activity with ELOVL5. The preference for n-3 over n-6 fatty acids was 251 
observed for both the 18- and 20-carbon substrates.  252 
 253 
The preference for n-3 fatty acids differs from a previous report of barramundi ELOVL 254 
activity, which found a preference for n-6 18-carbon PUFA (18:3n-6 over 18:4n-3) [18]. 255 
However the preference for n-3 over n-6 fatty acids was observed for the 20-carbon 256 
LCPUFA (20:5n-3 over 20:4n-6) by Mohd-Yusof et al [18] which is similar to our 257 
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findings. The peptide sequences were 100% identical between our ELOVL and that 258 
reported by Mohd-Yusof et al [18] but they employed a 72 hr incubation period (no detail 259 
of the concentration of substrates added). In addition, they did not perform yeast cell + 260 
medium mass balance calculations and did not examine 18:3n-3 and 18:2n-6 substrates as 261 
we have done, thus making a sensible comparison between the two studies difficult.  262 
 263 
Our results suggest that a potential bypass of the Δ6 desaturation involving an elongation 264 
of 18-carbon PUFA followed by a Δ8 desaturation, rather than the conventional Δ6 265 
desaturation followed by an elongation, is possible. In this model, the elongation products 266 
20:3n-3 and 20:2n-6 from 18:3n-3 and 18:2n-6, respectively, may be important in the 267 
synthesis of 22-carbon LCPUFA if the rate limiting Δ6 desaturation step is appreciably 268 
slow [21]. The converted 20:4n-3 and 20:3n-6 (desaturation products of 20:3n-3 and 269 
20:2n-6) could be further utilised by a Δ5 desaturation and the usual pathway. We have 270 
observed that fatty acyl desaturase (FADS) from barramundi has dual Δ6/Δ8 desaturase 271 
activity when the substrates 18:3n-3 and 20:3n-3 or 18:2n-6 and 20:2n-6 were available 272 
[16]. Thus, dietary 18:3n-3 and 18:2n-6 can be elongated by barramundi ELOVL and 273 
then desaturated by FADS2 to 20:4n-3 and 20:3n-6. The LCPUFA 20:4n-3 and 20:3n-6 274 
are immediate precursors of 20:5n-3 and 20:4n-6, respectively following the action of a 275 
Δ5 desaturase. However, it remains unclear whether the Δ5 desaturase actually exist and 276 
function in barramundi [16]. Fig. 3 illustrates the alternative pathway of ELOVL activity 277 
for LCPUFA conversion. Thus, the LCPUFA conversion from 18:3n-3 and 18:2n-6 278 
precursors in barramundi can be processed through either (1) a Δ6 desaturation pathway 279 
to form 18:4n-3 and 18:3n-6 and then through an elongation reaction to form the 280 
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downstream products 20:4n-3 and 20:3n-6 or (2) an initial elongation step to form 20:3n-281 
3 and 20:2n-6 and then followed with a Δ8 desaturation to form 20:4n-3 and 20:3n-6 282 
(Fig. 3).  283 
 284 
Elongation of 18:3n-3 and 18:2n-6 or 18:4n-3 and 18:3n-6 not only produces 20-carbon 285 
metabolites for subsequent Δ5 desaturation but it also could generate some 22-carbon 286 
products, i.e. 22:3n-3 and 22:2n-6, or 22:4n-6 and 22:3n-6. These 22-carbon fatty acids 287 
are considered as ‘dead-end’ products because they are not part of the classic LCPUFA 288 
synthesis pathway (Fig. 3). Whether these fatty acids are produced, and if they are stored 289 
in the tissue or can be utilised by other enzymes remains to be elucidated.   290 
 291 
From the time course experiments, we observed that most 18- and 20-carbon fatty acids 292 
disappeared in the culture and 18-carbon fatty acid substrate appeared to be lost more 293 
than 20-carbon substrate. For example, there was 5 times more 20-carbon substrate (25% 294 
of original substrate) left in the culture by 6 hr incubation than 18-carbon substrate (< 295 
5%). Only a small proportion of the exogenous fatty acids followed the biosynthetic 296 
pathway to be elongated to their longer chain metabolites, suggesting fatty acids are 297 
possibly oxidised by the yeast cells to produce energy [16,22]. Further, we have 298 
previously demonstrated that desaturation products also appear in the culture medium 299 
[16], emphasising the importance of measuring and taking into account any elongation 300 
products present in the medium in any calculation of enzyme activity. 301 
 302 
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In summary, we have examined a barramundi ELOVL gene which yielded a protein that 303 
exhibited the greatest elongase activity towards 20-carbon LCPUFA, and generally 304 
showed greater conversion of n-3 compared with n-6 substrates. Most importantly, the 305 
elongase has a capacity for the conversion of 18:3n-3 and 18:2n-6 to their 20-carbon 306 
products, suggesting an alternative pathway for LCPUFA conversion in barramundi. 307 
Bypassing the first (and limiting) Δ6 desaturation step has the potential to improve 308 
downstream LCPUFA conversion. However, whether this alternate pathway would be of 309 
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FIGURE LEGENDS 320 
Fig. 1. Time course of changes in fatty acid levels of elongation product after expressing 321 
barramundi elongase with addition of 18:4n-3 or 20:5n-3 fatty acid substrate at 250 μM 322 
in transformed yeast cultures. Fatty acid levels in cells (A), in remaining cell-free 323 
medium from yeast culture (B) and fatty acid in cells and medium were both taken into 324 
account (C) after addition of 18:4n-3. Fatty acid levels in cells (D), in remaining cell-free 325 
medium from yeast culture (E) and fatty acids in cells and medium were both taken into 326 
account (F) after addition of 20:5n-3. Mean ± SEM, n=3.  327 
 328 
Fig. 2. Dose-response of 18:4n-3, 20:5n-3 or 18:3n-3 at 0−500 μM for 24 hr on 329 
barramundi elongase activity and production of n-3 LCPUFA. Effect of 18:4n-3 on 330 
biosynthesis of 20:4n-3 and 22:4n-3 in cells (A), in remaining cell-free medium from 331 
yeast culture (B) and fatty acids in cells and medium were both taken into account (C). 332 
Effect of 20:5n-3 on synthesis of 22:5n-3 and 24:5n-3 in cells (D), in remaining cell-free 333 
medium from yeast culture (E) and fatty acids in cells and medium were both taken into 334 
account (F). Effect of 18:3n-3 on synthesis of 20:3n-3 and 22:3n-3 in cells (G), in 335 
remaining cell-free medium from yeast culture (H) and fatty acids in cells and medium 336 
were both taken into account (I). Elongation products were quantitatively computed as µg 337 
of fatty acids per total cell, medium or total cell + medium. Mean ± SEM, n=3.  338 
 339 
Fig. 3. A postulated bypass (dashed line) of LCPUFA biosynthesis utilising an elongation 340 
pathway in barramundi. Bold font indicates n-3 fatty acids and non-bold font indicates n-341 
6 fatty acids.  342 
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Table 1. Substrate specificity and enzyme activity 
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were used for calculating the conversion (%). Data are 
means ± SEM of n ≥ 3. Conversion (%) = [cellular product / (cellular substrate + cellular 
product) × 100]. 
c
Elongated fatty acid products in medium were also taken into account for calculating the 
conversion (%). Data are means ± SEM of n ≥ 3. Conversion (%) = [cellular and 
extracellular product / (cellular substrate + cellular and extracellular product) × 100].  
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Supplementary data 1. Primers used in the study 
 













Qi-R (nested PCR) GAGGACTCGAGCTCAAGC 
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